 Mechelen, Belgium; 14 July 2021; 2 2 . 01 CET ; regulated information Galapagos NV Euronext Nasda q : GLPG reports topline results with GLPG3970 in three pati e nt studies . GLPG3970 , the first product candidate from a broad portfolio of SIK inhibitor compounds, provides clinical data supporting the role of SIK inhibition in inflammation. SIK is a novel target class discovered by Galapagos . 